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Abstract In this report, comparisons between molecular 
affinities and cellular proliferation activities have been made 
for insulin-like growth factor-I (IGF-I) and two IGF-I fusion 
proteins in order to evaluate fusion proteins as tools for receptor 
binding studies. Binding affinities and growth promoting effects 
of the N-terminal fusion Z-IGF-I and the C-terminal fusion IGF-
I-Z, and native recombinant human IGF-I, were analyzed. 
Binding kinetic properties of the three IGF-I variants were 
analyzed using BIAcore kinetic interaction analysis testing for 
binding to both human IGF binding protein 1 (IGFBP-1) and a 
soluble form of the human IGF type I receptor extracellular 
domains (sIGF-IR). The growth promoting effects on SaOS-2 
human osteosarcoma cells of the different fusion proteins were 
analyzed. A comparison of receptor binding affinities and growth 
promoting effects shows that the fusion protein receptor affinity 
does not correlate with proliferative potential. The IGF-I-Z 
fusion, with the lowest receptor affinity, shows similar prolif-
erative potential to native IGF-I. However, the Z-IGF-I fusion 
protein, with twice the receptor affinity of IGF-I-Z, displays only 
about 70% of the IGF-I-Z growth promoting activity. Both IGF-
I fusion proteins possess similar affinity to IGFBP-1. These 
results indicate that determinants other than the receptor affinity 
could be involved in the regulation of IGF-I proliferative action. 
This study demonstrates that ligand fusion proteins may be useful 
to study mechanisms of ligand induced receptor activation. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Insulin-like growth factor-I (IGF-I) is a small, 7.6 kDa 
protein which stimulates a variety of growth promoting and 
metabolic effects. The bioactivities of the IGF molecules in 
circulation are modulated by a group of specific high affinity 
binding proteins (IGFBPs), which share no sequence homol-
ogy with IGF receptors. Seven distinct IGFBPs (IGFBP-1-7) 
have to date been characterized in mammalian systems [1-3]. 
The cellular response to IGF-I is primarily mediated through 
"■Corresponding author. 
Abbreviations: CD, circular dichroism; EDC, JV'-ethyl-JV'-(dimethyl-
aminopropyl)-carbodiimide; NHS, iV-hydroxysuccinimide; IGF-I, 
insulin-like growth factor-I; IGFBP-1, insulin-like growth factor 
binding protein-1; IGF-IR, insulin-like growth factor-I receptor; 
sIGF-IR, soluble insulin-like growth factor-I receptor extracellular 
portion; RU, resonance units; Gdn-Hcl, guanidine hydrochloride; 
FCS, fetal calf serum; PFPA, pentafluoropropionic acid 
the specific interaction between IGF-I and the cellular IGF-I 
receptor (IGF-IR) [4]. Both IGF-IR and the homologous in-
sulin receptor are suggested to be activated through a ligand 
induced conformational change and subsequent trans-phos-
phorylation of the intracellular tyrosine kinase domains lead-
ing to mitogenic and metabolic signaling [5-8]. In this study, 
we explore the use of IGF-I fusion proteins to study IGF-I 
specific protein-protein interactions. We decided to test IGF-I 
binding properties as fusions to the IgG binding Z domain, a 
63 amino acid protein frequently used as an affinity handle [9]. 
Z domains have been extensively used as fusion partners in 
recombinant production systems to increase the production of 
the desired protein, to solubilize the protein product and as an 
important tool for purification and detection of a variety of 
recombinant proteins [9,10]. The Z protein is well character-
ized, and a NMR solution structure has recently been pub-
lished [11]. The fusion protein production approach was chos-
en to serve several purposes. The use of fusion proteins in the 
analysis of specific protein interactions has some major ad-
vantages, the predominant one being ease of production and 
purification of proteins with altered biochemical characteris-
tics, i e. mutated variants. The production of IGF molecules 
meets certain difficulties and makes specific demands on pro-
duction and purification, such as the need to refold the mol-
ecule and specifically purify only the correctly folded variant 
with native disulfide pairing, generally resulting in low yields. 
The successful use of the Z domain in facilitating IGF-I pro-
duction has been described previously. The use of a fusion 
protein is further likely to affect the binding kinetic properties 
and therefore modulate the binding equilibria for the different 
interactions. N- and C-terminal fusions may differentially in-
hibit binding to either receptor or binding protein, thereby 
possibly providing tools to rationalize the signaling properties 
of the IGF molecules. A comparison was made between N-
and C-terminal fusions to IGF-I and the native unfused mol-
ecule for their ability to bind to IGFBP-1, and to IGF-IR as 
well as cell proliferative activities. We demonstrate that the 
cell proliferative potency is not correlated with receptor affin-
ity in this system. The different properties of the fusion pro-
teins used in terms of both receptor and IGFBP binding could 
be potentially useful to create tools for dissecting IGF signal-
ing mechanisms such as receptor conformational rearrange-
ments and intracellular phosphorylation pathways. 
2. Materials and methods 
2.1. Production and purification of IGF-I proteins 
IGF-I was produced as fusion to the 63 amino acid synthetic im-
munoglobulin G (IgG) binding domain Z, derived from the B-domain 
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of staphylococcal protein A [12]. The Z-IGF-I protein was produced 
using an Escherichia coli intracellular production system. E. coli RV 
308 transformed with the production vector pKP522 [13] was grown 
in a 5 1 bioreactor in minimal medium supplemented with 1% yeast 
extract. Proteins were released by dissolving harvested cells in 6 M 
Gdn-HCl. The suspension was diluted to a final Gdn-HCl concentra-
tion of 1 M, using 1 XTST (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 
0.05% Tween 20) and centrifuged before passing the supernatant over 
an IgG Sepharose 6FF affinity chromatography column (Pharmacia 
Biotech, Uppsala, Sweden). The column was washed with 10 column 
volumes of 1 X TST buffer. The pH was lowered by washing the col-
umn with two column volumes of 5 mM ammonium acetate pH 5. 
The fusion protein was eluted with 0.2 M acetic acid pH 2.8. The 
protein eluate was subsequently concentrated to approximately 2 mg/ 
ml by ultrafiltration using a Filtron Omegacell (Filtron Corp., North-
borough, MA, USA) with 3 kDa cut-off. Final purification was per-
formed by reverse phase HPLC with a linear gradient of 35^2% 
acetonitrile/water, 0.25% PFPA, at 1 ml/min over 50 min at a temper-
ature of 50°C using a Kromasil KR-100-10 C8 (4.6x250 mm) column 
(Eka Nobel, Surte, Sweden). The protein was finally lyophilized and 
stored at —80°C. IGF-I-Z protein was produced using an E. coli 
secretion production system where the desired product is fused to a 
synthetic signal peptide and secreted to the periplasmic space. The E. 
coli strain UL 632 (L. Isaksson, personal communication) trans-
formed with plasmid pKP1026 was grown in a 5 1 bioreactor. Har-
vested cells were treated by cold osmotic shock [14] and the released 
periplasmic protein fraction was purified using IgG affinity chroma-
tography. The affinity chromatography was performed as described 
above except that the column was equilibrated in 150 mM ammonium 
acetate pH 7.5. Final purification was by RP-HPLC using a gradient 
of 33^10% acetonitrile, 0.25% PFPA using the same column as before. 
Native recombinant IGF-I was prepared as described elsewhere 
[15,16]. 
2.2. IGF-I receptor 
Soluble recombinant human IGF-IR was produced in human 293 
kidney cells [7]. The transmembrane and intracellular tyrosine kinase 
parts of the C-terminal ß-domain have been replaced by the IgG 
binding Z domain (8.1 kDa). The secreted soluble form of the recep-
tor forms an (αβ'Ζ)2 receptor ectodomain moiety. The receptor was 
purified from conditioned cell medium using IgG Sepharose affinity 
chromatography as described [7]. The acid eluted material was col-
lected in tubes containing one-third of the eluted volume of 1 M 
HEPES pH 8 in order to neutralize the eluted material and retain 
the purified receptor at a pH where activity is preserved. The receptor 
material was concentrated by ultrafiltration and stored in aliquots at 
-80°C. 
2.3. Production and purification of IGFBP-1 
Recombinant human IGFBP-1 was produced in DON cells trans-
fected with a papilloma viral vector containing an expression cassette 
with the cloned human IGFBP-1 gene under the control of a BPV 
promoter [17]. The medium was clarified from cells by centrifugation 
and the supernatant was applied to an IGF-I Sepharose column, 
prepared from CNBr activated Sepharose CL-4B (Pharmacia Bio-
tech), equilibrated with 1 X TST. After sample application, the column 
was washed with five column volumes of TST followed by five vol-
umes of 5 mM ammonium acetate at a linear flow rate of 5 cm/min. 
Bound IGFBP-1 was eluted using 1 M acetic acid pH 2.8 at the same 
flow rate. Eluted material was further applied to an S-Sepharose cat-
ion exchange column (Pharmacia Biotech) equilibrated with a buffer 
containing 90% 20 mM ammonium acetate pH 4.5 and 10% 500 mM 
ammonium acetate pH 7.0. After washing with equilibration buffer, 
the IGFBP-1 was eluted with a linear gradient of 10-70% 500 mM 
ammonium acetate pH 7.0 in 20 mM ammonium acetate pH 4.5 over 
30 min, at a flow rate of 1 ml/min. Thereafter, purified IGFBP-1 
protein was lyophilized and stored at —20°C. 
2.4. Z protein 
Pure Z protein was used as control in the BIAcore measurements. 
The Z protein was produced intracellularly in E. coli and IgG affinity 
purified as described elsewhere [18]. 
2.5. Protein analysis 
Quantitative amino acid composition analyses were determined by 
acid hydrolysis followed by analysis using a Beckman 6300 amino 
acid analyzer, equipped with a System Gold data handling system 
(Beckman, Fullerton, CA, USA). Protein homogeneity was evaluated 
by SDS-PAGE or by RP-HPLC. 
2.6. Circular dichroism 
CD spectra were recorded using a Jasco J720 spectropolarimeter 
(Jasco Inc., Japan). Protein samples were dissolved in 10 mM potas-
sium phosphate buffer pH 7.0, to a final concentration of 0.1 mg/ml. 
Spectra were recorded at 250-184 nm at a step resolution of 0.1 nm 
and a scanning speed of 5 nm/min, using 1 mm cuvettes. Each spec-
trum is the average of five accumulated scans. Actual concentration of 
each protein sample was determined, after recording spectra, by quan-
titative amino acid composition analysis. 
2.7. Biosensor analysis 
The BIAcore Sensorchip CM5 (certified grade), surfactant P20 and 
amine coupling reagents Ar'-ethyl-A'''-(dimethylaminopropyl)-carbodi-
imide (EDC), iV-hydroxysuccinimide (NHS) and ethanolamine hydro-
chloride were obtained from Biacore AB (Uppsala, Sweden). All other 
buffer chemicals were obtained from Sigma (St. Louis, MO, USA) or 
Fluka (Buchs, Switzerland). All kinetic measurements were performed 
with the larger molecule IGFBP-1 or IGF-IR, respectively, as the 
immobilized acceptor molecule. Immobilization of IGFBP-1 was per-
formed at 5 μΐ/min in l x H B S (10 mM HEPES, pH 7.4, 150 mM 
NaCl, 3.4 mM EDTA, 0.05% P20) as driving buffer. IGFBP-1 was 
dissolved in 50 mM sodium acetate pH 4.7, at a concentration of 50 
mg/ml. The protein was immobilized via primary amine groups as 
previously described [19] utilizing EDC/NHS carbodiimide coupling 
reagents, to a final resonance value between 700 and 2000 resonance 
units (RU). IGF-I receptor immobilization was performed by a sim-
ilar procedure at pH 4. Final levels of IGF-IR immobilization were 
6500-7500 RU. All experiments were performed using 1 X HBS as 
driving buffer at a flow rate of 8 μΐ/min. The injection of analyte 
was controlled using the kinject command in the Bialogue control 
software. Each sample was injected twice at five different concentra-
tions in random order over the same surface in each measurement 
series. The concentrations used in IGFBP-1 kinetics were: IGF-I: 327, 
109, 54.5, 27.3, 13.6 nM; Z-IGF-I and IGF-I-Z: 300, 100, 50, 25, 12.5 
nM. Each protein was analyzed using at least two separate experi-
ments, with independent acceptor molecule immobilizations. The cal-
culated rates are the mean values of each measurement series. Kinetic 
measurements were performed by injection of each analyte for 300 s 
followed by disassociation in buffer flow for 400 s. The immobilized 
IGFBP-1 was regenerated after each cycle using a 12 μΐ injection of 
100 mM HC1. IGF-I ligand concentration used in receptor measure-
ments were for native IGF-I: 262, 131, 66, 33, 16.5 nM; Z-IGF-I: 
350, 177, 88.6, 44.3, 22.1, 11 nM; IGF-I-Z: 381, 191, 95.5, 47.8, 23.9, 
11.9 nM. The immobilized IGF-IR surface was regenerated after each 
cycle by injection of 12 μΐ acidic regeneration solution containing 0.3 
M sodium citrate pH 5 and 0.4 M NaCl. Ligand samples were injected 
twice at six different concentrations in random order over the same 
surface in each measurement series. The temperature in all kinetic 
experiments was 298 K. Unfused Z at 300 nM was used as control 
for non-specific Z-derived interactions. Kinetic parameters were cal-
culated using the kinetics evaluation software package, BIAevaluation 
2 (Biacore AB). The theory of calculating kinetic binding parameters 
from BIAcore measurement techniques has been extensively described, 
for a review see [20]. 
2.8. Cell proliferation assay 
The relative proliferative activity of the different proteins was tested 
on human osteosarcoma SaOS-2 cells. Cells, at a density of approx-
imately 30000 cells/ml, were seeded in 96 well plates in 100 ml of 
McCoy medium supplemented with 15% fetal calf serum (FCS) (Hy-
Clone, Logan, UT, USA) and 1000 units/ml PEST (penicillin/strepto-
mycin) (Sigma). Cells were incubated for 24 h and the media were 
replaced with McCoy containing 0.1% HSA. Following an additional 
24 h incubation the test proteins were added in concentrations from 
0.06 nM to 2.5 nM. Aliquots of lyophilized test protein were dissolved 
and diluted directly in HSA containing serum free growth medium, 
immediately before addition. Cells were incubated for 72 h before 
determining the metabolic response using EZ4U colorimetrie assay 
quantification according to the manufacturer's instructions (Biomed-
ica, Austria). 
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Fig. 1. Schematic representation of the used fusion proteins, Z-IGF-
I and IGF-I-Z. The molecular mass of the proteins is (A) 7649 Da 
(70 residues), (B) 16927 Da (152 residues) and (C) 15726 Da (142 
residues). 
3. Results 
3.1. Protein production and purification 
All the protein components IGF-I, IGF-I-Z, Z-IGF-I, 
sIGF-IR and IGFBP-1 were produced and purified to obtain 
highly characterized proteins to be assayed in binding and 
biological assays. The Z-IGF-I and IGF-I-Z fusion proteins, 
as outlined in Fig. 1, were produced in E. coli and purified to 
homogeneity. Both preparations were estimated to be more 
than 95% pure by SDS-PAGE (Fig. 2), or by RP-HPLC anal-
ysis. The IGF-I receptor was essentially homogeneous after 
the one step IgG affinity purification. The receptor was pro-
duced and purified as a homogeneous (αβ'Ζ)2 moiety. The 
receptor was glycosylated to 26.1% by mass [7]. IGFBP-1 
was purified to homogeneity and determined to be more 
than 90% pure by SDS-PAGE. The amino acid composition 
contents were according to what was expected from the re-
spective deduced amino acid sequences (data not shown). 
3.2. Circular dichroism 
Far UV circular dichroism was applied to monitor the sec-
ondary structure content and possible differences between the 
IGF-I fusions. The far UV spectra of Z-IGF-I and IGF-I-Z 
were normalized according to quantitative amino acid analysis 
of the actual samples (Fig. 3). The spectra are very similar and 
mostly overlap over the entire wavelength range, indicative 
that the overall secondary structure content was the same in 
both fusion proteins. 
3.3. BIAcore measurements 
The determination of the kinetic parameters and the asso-
ciation equilibrium constants was performed using the label 
Fig. 2. SDS-PAGE of the purified fusion proteins. Lane 1, Z-IGF-
I; lane 2, IGF-I-Z; lane 3, IGF-I; lane 4, Z domain. 
free, real time BIAcore biosensor technology. The larger ac-
ceptor molecules IGF-IR and IGFBP-1 were immobilized in 
two separate sets of experiments and the IGF-I analytes 
passed over the acceptor molecule surface. A representative 
Sensorgram showing relative response vs. time of IGF-I bind-
ing to IGF-IR is shown in Fig. 4. The binding kinetic param-
eters derived from the BIAcore data of the IGF-I variants 
binding to IGFBP-1 and IGF-IR are summarized in Table 
1. The cumulative error in the determined association con-
stants from all runs was estimated to be less than 12%, 
when calculated as the square root of the sum of the squares 
of the errors in amino acid analysis, pipetting and data fitting. 
The association rates of the IGF-I fusions are slowed down 
for both IGFBP-1 and IGF-IR binding to about the same 
extent. The disassociation rates shows that Z-IGF-I has a 
similar koS as that of native IGF-I for IGFBP-1 binding 
and about 1.5 times slower k0g for IGF-I
R binding. The re-
verse is seen for IGF-I-Z with somewhat higher koi! for 
IGFBP-1 binding and close to native koS for IGF-I
R. The 
derived association equilibrium constant KA shows the 
IGFBP-1 binding to be reduced to a similar extent for both 
fusions, approximately 1.8 times, whereas receptor binding is 
reduced by 2.4 times for Z-IGF-I and by 4.7 times for IGF-I-
Z, respectively. 
3.4. Proliferation assay 
The IGF-I fusion proteins' proliferative response was tested 
in cell proliferation assays using human SaOS-2 cells, and the 
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Fig. 3. Superposition of the far UV CD spectra, between 185 and 250 nm, of Z-IGF-I and IGF-I-Z. 
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Fig. 4. BIAcore analysis of IGF-I binding to immobilized IGF-IR-
Z. The sensorgram shows the relative response in RU after back-
ground subtraction versus time in seconds. The concentrations of 
IGF-I is indicated by numbers in the graph. The ligand association 
phase injection time was 300 s followed by dissociation in buffer 
flow for 900 s at a low rate of 8 μΐ/min. 
EZ4U colorimetrie based system. The growth promoting ef-
fects of the different proteins in the used concentration range 
is shown in Fig. 5. The data are expressed as percent stimu-
lation of internal standard containing 10% FCS. IGF-I and 
IGF-I-Z reach about 75% of maximal FCS stimulation where-
as Z-IGF-I reaches about 55%. 
4. Discussion 
In this paper, we have analyzed in vitro binding character-
istics, as well as in vivo biological proliferation activities, of 
fusion proteins based on IGF-I. The IGF-I variants represent 
C- and N-terminal fusions to a one domain protein A ana-
logue (designated Z) of 58 amino acid residues. This domain 
was chosen on the basis of being a highly stabile domain with 
a known fold and its well characterized advantages as an 
affinity fusion partner for the production of IGF molecules. 
Affinities to sIGF-IR and IGFBP-1 were studied and both 
types of fusions showed a similar weakened affinity to 
IGFBP-1. However, the relative affinities to sIGF-IR differed 
significantly between the Z-IGF-I and IGF-I-Z proteins. The 
structural properties of the fusion proteins were tested by 
circular dichroism. The data suggest that the overall second-
ary structure content is similar for both fusion proteins. The 
relative locations of the two domains do not drastically 
change the packing of the fusion proteins, which could possi-
Table 1 
Summary of kinetic data 
IGFBP-I and IGF-IRZ 
of IGF-I fusion proteins binding to 
Ligand 
Binding to IGF-IR 
kon/ (M"
1 s"1 X10"5) 
/ ^ ( s ^ X l O 4 ) 
KA/ (M
_ 1 X 10~9) 
AAGI (kcal т о Г 1 ) 
Binding to IGFBP-I 
к ч (Mr
1 sT1 X 10~5) 
^ / ( s ^ X l O 4 ) 
KA/ (M"
1 X 10"9) 
AAGI (kcal т о Г 1 ) 
IGF-I 
4.7 
16.7 
0.28 
0 
6.1 
3.5 
1.7 
0 
Z-IGF-I 
1.3 
10.7 
0.12 
0.50 
3.5 
3.5 
1.0 
0.31 
rei. rate 
0.28 
0.64 
0.43 
0.57 
1 
0.59 
IGF-I-Z 
1.1 
17.9 
0.06 
0.91 
4.3 
4.5 
0.96 
0.34 
rei. rate 
0.23 
1.07 
0.21 
0.70 
1.29 
0.56 
0,00 0,500 1,00 1,50 
cone [nM] 
2,00 2,50 
The relative rates are expressed as the fraction of unfused IGF-I rates 
to each acceptor molecule. 
Fig. 5. Representation of the growth stimulating effects of the IGF-
I fusion proteins. The stimulatory effect, monitored with the EZ4U 
assay, is expressed as percent of FCS internal control and plotted 
against concentration of ligand. The symbols used are: · , IGF-I; 
X, Z-IGF-I; Δ, IGF-I-Z. The values shown are the mean of two 
separate experiments performed in eight separate samples at each 
concentration. 
bly be the case since IGF-I has been shown to be sensitive to 
structural aberrations [24]. Recombinant IGF-I accumulates 
as two distinct folding forms, native and mismatched, differ-
ing in their disulfide bond arrangement, the mismatched form 
having structural aberrations, decreased a-helicity, and dimin-
ished or even absent IGFBP and IGF-IR binding [15,25]. The 
produced IGF-I fusion proteins both display high affinity 
binding to IGFBP-1 and IGF-IR, which is only the case for 
correctly folded material. The preparations are homogeneous 
as determined by HPLC and SDS-PAGE analysis. Since the 
mismatched form possesses distinctly different elution profiles 
on reverse phase compared to native form, the purified fusion 
proteins are concluded to be in the correct disulfide confor-
mation. 
BIA analysis enables the determination of both association 
rate and dissociation rate, hence distinguishing between on-
rate and off-rate in the contribution to the equilibrium bind-
ing constant. The on-rate for the fusion proteins is slowed 
down compared to native IGF-I, both for IGFBP-1 and for 
IGF-IR association (Table 1). The association with the recep-
tor is more affected than IGFBP-1 binding which could reflect 
a more complicated binding mechanism for IGF-I to its re-
ceptor where the receptor association is accompanied by a 
conformational change of the receptor [7]. Association of 
IGF-I with the receptor involves determinants from both ot-
subunits and covers a large part of the ligand. The basic IGF-
I (pi 8.3) fused to the acidic Z (pi 5.7) could lead to an 
electrostatic attraction between the two fusion halves at neu-
tral pH. Some of the initial electrostatic attraction between 
IGF-I and the receptor might be diminished by a close contact 
between IGF-I and its fusion partner. This should be seen as a 
lowered on-rate since medium range electrostatic attraction is 
an early step in the formation of protein-protein complexes. 
The fusion protein may also simply hinder the structural re-
arrangement resulting in slower on-rates. The off-rates show 
changes in both receptor and IGFBP-1 binding, differing be-
tween the fusions. Predominant, though, is the decreased dis-
association of Z-IGF-I from IGF-IR. A decreased disassocia-
tion rate leading to prolonged signaling might have 
consequences for both cellular responses and the rate of re-
ceptor turnover. The influence on off-rates is smaller than on 
the on-rates, indicating that the sites of specific binding are 
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not, or to a lesser extent, affected by the presence of the fusion 
partner. 
The relative locations of the domains in the fusion proteins 
have not been established. The N- and C-termini are sepa-
rated by 21 A in the model built structure of IGF-I [26], 
compared to only 5 A in the NMR structure [27]. However, 
the NMR structure lacks distance restraints (NOEs) for both 
N- and C-termini. This indicates a large flexibility which 
makes modeling of the relative locations of the IGF-I and Z 
domains of the two fusion proteins difficult. The integrity of 
the IGF-I N-terminus is necessary to maintain IGFBP bind-
ing. The naturally occurring variant of IGF-I, desl-3 IGF-I, 
lacking the first three amino acids, drastically lowered IGFBP 
binding compared to native IGF-I [28]. Previous reports on 
the IGF-I interaction with IGFBP-1 have claimed that N-
terminal extensions of the molecule hinder the IGF-I binding 
to IGFBP-1 (Long-R3-IGF-I/long IGF-I) [29]. IGF-I receptor 
specificity has been studied previously using fusion proteins 
[30], using the flag epitope purification system. No difference 
in receptor specificity was reported, although the absolute 
value of binding was lowered for the fusion compared to 
native IGF-I. The predominant difference between Z fusions 
and the other described IGF-I fusions is that the Z fusion 
partner is a characterized molecule with a well defined specific 
fold of known three-dimensional structure. A shorter fusion 
partner such as the flag epitope, a His-tag or subdomains of 
other proteins, e.g. Long-R3 with a 13 amino acid extension, 
may not form an independently folding unit and possibly fold 
back on the major domain and interfere with some specific 
binding determinants, thus altering binding strength. Thus, 
the use of intact domain fusions seems favorable if retained 
binding is desired. 
Most interestingly, the prohferative effects measured using 
the colorimetrie EZ4U assay demonstrate that the sIGF-IR 
affinity and the growth promoting effects are not correlated: 
IGF-I-Z has only 21% of the native IGF-I receptor affinity 
but is still as potent as a prohferative agent. Z-IGF-I has 41% 
of the receptor affinity but a much reduced prohferative effect. 
Thus, fusion proteins with high affinity for the receptor may 
not necessarily be a potent mitogen because more than one 
interaction to the receptor is likely to be involved in receptor 
signaling [5-7]. The IGF-I fusion's IGFBP-1 affinities are 
within error identical, about 60% of native, suggesting that 
IGFBP binding is not an explanation. However, the IGFBP 
expression pattern for the SaOS-2 cells was not studied. There 
are at least seven different IGFBP molecules. If the relative 
affinities to other IGFBPs differed between the two IGF-I 
fusions, this might contribute to the observed difference in 
prohferative potential. Therefore, an additional experiment 
using [3H]thymidine incorporation with CHO-DG44 cells 
was performed (data not shown). The results were similar, 
as defined by the same ranking of the fusion proteins in their 
prohferative potential. This shows that the relative order of 
the three IGF-I variants is not sensitive to the choice of cell 
type in the analysis or the method of analysis of the prohfer-
ative response. Another explanation is that the fusion partners 
affect the receptor signal transduction mechanism differently 
by steric hindrance. The IGF-I receptor activation involves 
several steps, the binding of a ligand using determinants 
from both α-subunits, inducing a conformational change 
and thus transferring the signal to the cytoplasmic tyrosine 
kinase domains. The signaling also involves a timing event 
and the duration of the signal, i.e. the ligand dissociation 
rate, is believed to be the efficiency determining step in recep-
tor activation potential [5,6,21]. Recent studies from our lab-
oratory have also demonstrated that binding of IGF-I to 
IGF-IR is accompanied by a large decrease in entropy, com-
patible with a structural rearrangement of the extracellular 
receptor domains [7]. Differences in the fusion proteins' ability 
to allow receptor conformational changes, imposed by steric 
hindrance, or to allow the formation of correct receptor sig-
naling conformation might change the signaling properties of 
the fusion proteins. Different structural rearrangements could 
lead to different receptor kinase activity or different phospho-
rylation patterns affecting both intracellular signaling path-
ways and receptor turnover. As recently demonstrated by 
Reddy et al. [22], receptor affinity per se is not correlated 
with mitogenic potency in the EGF/EGFR system. A single-
site EGF mutant (Y13G) with 50-fold lowered receptor affin-
ity was more potent than the wild type due to decreased 
ligand depletion and less induction of receptor down-regula-
tion. It has further been demonstrated that the insulin recep-
tor ß-domain tyrosine kinases are asymmetrically trans-phos-
phorylated upon ligand binding and activation [23]. The Z-
IGF-I and IGF-I-Z bind IGF-IR with high affinity but could 
possibly alter the receptor phosphorylation pattern due to 
simple steric hindrance of the α-subunit conformational 
change. Taken together, this demonstrates that affinity and 
efficiency are not directly linked in the events of IGF-I recep-
tor activation since other factors such as receptor trafficking 
and signaling dynamics complicate the picture. 
In conclusion, this work shows that kinetic binding proper-
ties of the used IGF-I fusion proteins do not correlate with 
biological activity in the IGF signaling system. This study 
exemplifies a characterization of a system where the order 
of the fusion protein components not only changes kinetic 
binding properties but also differentially changes the mitogen-
ic activity properties. The exact nature of the influence of the 
different IGF-I fusions on the receptor trafficking is subject to 
future investigations. The use of fusion proteins to alter the 
kinetic and dynamic properties of a given ligand seems prom-
ising as a tool in the dissection of intracellular signaling 
events. 
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